Common questions about Abhayrab (FAQ)
Q: What is the primary purpose of the Abhayrab vaccine?
The official purpose of the Abhayrab vaccine is to help prevent rabies, both through pre-exposure prophylaxis (PrEP) before an exposure occurs, and as part of post-exposure prophylaxis (PEP) after a potential exposure. Official documents describe it as being used to stimulate the body's protective immune response against the rabies virus.
Q: Is Abhayrab the only treatment used after a potential rabies exposure?
According to regulatory guidance on post-exposure prophylaxis (PEP), Abhayrab is typically not the only treatment administered. For individuals who have not been previously vaccinated, Human Rabies Immune Globulin (HRIG) is described in guidance documents as being administered along with the first dose of the vaccine.
Q: What is the difference between Abhayrab and Rabies Immunoglobulin (RIG)?
The vaccine (Abhayrab) creates active immunity by prompting your body to produce its own protective antibodies, which takes several days. In contrast, Rabies Immunoglobulin (RIG) provides passive immunity by supplying ready-made antibodies, which are intended to provide immediate support until the vaccine takes effect.
Q: What is the real or generic name for the medicine marketed as Abhayrab?
Abhayrab belongs to a class of medicines known as Rabies Vaccine, Human. Specifically, official product information identifies it as a Purified Vero Cell Rabies Vaccine (PVRV), which contains the inactivated rabies virus antigen.
Q: Why do people who work with animals need a preventive Abhayrab vaccine schedule?
Preventive vaccination (PrEP) is generally recommended by regulatory bodies for high-risk occupational groups. These groups include veterinarians, laboratory staff who handle the virus, animal handlers, and wildlife officers, whose work involves potential exposure to the rabies virus.
Q: What types of animals typically transmit the rabies virus to humans?
Official guidance on rabies exposure identifies various animals as potential carriers. Transmission most commonly involves certain wild animals, such as bats, raccoons, skunks, and foxes, though domestic animals including dogs and cats can also transmit the virus in some regions.
Q: How quickly is Abhayrab expected to start working in the body?
Official product guidance states that the active immune response that generates protective antibodies is often observed to begin developing 7 to 10 days after administration. This process requires time as the body builds its specific immune defense.
Q: What happens if someone misses one of the shots in the Abhayrab vaccination series?
Regulatory guidance states that minor delays (a few days) in the post-exposure schedule do not generally affect the outcome. However, longer delays, such as those lasting weeks or months, are not well-studied and may lead to a reduced immune response.
Q: Why might a patient feel dizzy or fatigued after receiving the Abhayrab injection?
Official documentation lists dizziness and malaise (a general feeling of discomfort) among the common systemic effects reported after vaccination. These events are described as common systemic reactions reported as the body mounts an immune response.
Q: Is there a reported connection between Abhayrab and muscle or joint pain?
Regulatory safety information indicates that muscle pain (myalgia) is classified as a very common reaction following administration. Joint pain (arthritis) is also noted in surveillance reports, but it is classified as an extremely rare adverse reaction.
Q: Can Abhayrab be administered to pregnant or breastfeeding women?
Official guidance states that since rabies is almost always fatal, pregnancy and breastfeeding are not usually cited as contraindications for initiating post-exposure prophylaxis (PEP) due to the severity of the disease. Studies have indicated no increased risk for spontaneous abortions or fetal abnormalities after administration during pregnancy.
Q: Is Abhayrab safe for use in infants and young children?
Yes, the vaccine is authorized and approved by regulatory bodies for use in individuals of all ages, including newborns and infants who require rabies prophylaxis. The administration site and dose may be adjusted based on the child's age, but it is indicated across the pediatric population.
Q: Are there any specific chronic health conditions that make a person ineligible for Abhayrab?
For post-exposure prophylaxis (PEP), there are generally no health conditions that serve as an absolute contraindication. However, for pre-exposure prophylaxis (PrEP), a history of severe hypersensitivity to any vaccine component or the presence of a severe acute or chronic progressive illness may limit its use.
Q: Does Abhayrab interact with common over-the-counter pain relievers?
According to regulatory guidance, common over-the-counter anti-inflammatory or pain-relieving medicines, such as paracetamol (acetaminophen), may be used. Regulatory guidance notes that these medicines are often used to address mild adverse reactions like fever or pain following vaccination.
Q: What is meant by 'post-exposure prophylaxis' in relation to Abhayrab?
Post-exposure prophylaxis (PEP) is the term used to describe the emergency treatment regimen that is started as soon as possible after a person has been potentially exposed to the rabies virus, for example, through a bite or scratch from a potentially rabid animal.
Q: Why is proper wound cleaning important before receiving the Abhayrab vaccine?
Official guidance on exposure management emphasizes that thorough wound cleaning is a critical first step in rabies prevention, as it works by lowering the viral load at the exposure site. Prompt irrigation with soap and water or povidone-iodine solution is advised.
Q: Does Abhayrab's effectiveness change if there is a delay in starting the treatment course?
Post-exposure treatment should be started as soon as possible following exposure. However, official guidance indicates that PEP may be initiated regardless of the time elapsed, although long delays (weeks or months) may result in a reduced or inadequate immune response.
Q: What is the minimum age that Abhayrab is generally authorized for use?
The official product labeling states that Abhayrab is authorized for use in individuals of all ages, including newborns and infants, when rabies prophylaxis is medically indicated.
Q: Why is it important that Abhayrab is not administered into the gluteal region?
Administration into the gluteal region (buttock) is strictly avoided. Gluteal administration is avoided due to the documented risk of unpredictable absorption, and the potential for sciatic nerve damage is noted in administration warnings.
Q: What is the significance of the Abhayrab vaccine being classified as an inactivated vaccine?
The classification of Abhayrab as an inactivated (killed virus) vaccine is significant because it means the vaccine contains only non-living rabies viral particles. Therefore, it is made from non-living particles, meaning it is not associated with the risk of causing the disease itself.
Q: Does Abhayrab contain any preservatives, and are they considered safe?
Regulatory documents for the standard formulation of the vaccine indicate that it contains Thiomersal as a preservative. This component is added to maintain the integrity of the product.
Q: What is the importance of having Inj. Adrenaline available when administering Abhayrab?
As with any injectable vaccine, official safety precautions note that epinephrine (adrenaline) is required to be readily available during administration. This is done to manage the rare but serious risk of a systemic allergic reaction, known as anaphylaxis, should it occur.
Q: Is it true that Abhayrab must be administered by a healthcare professional only?
Yes, Abhayrab is administered via injection and, according to product labeling and administration guidelines, is intended to be given by a healthcare professional in a clinical or medical setting.
Q: Are there any studies that have examined the long-term protection offered by Abhayrab boosters?
Official guidance recognizes the use of a single booster dose to maintain adequate levels of protective antibodies (serum titers) in individuals who remain at high risk of exposure. These boosters are used to help maintain long-term antibody levels, particularly for individuals whose titers may have fallen below the established protective threshold.
